/
Neurology
Multiple System Atrophy
18
Pipeline Programs↗
27
Active Trials↗
14
Companies Involved↗
Multiple System Atrophy is an emerging landscape with 18 programs across 14 companies. The most active players are Yoda Therapeutics Inc., Teva, Lundbeck. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 18
Phase 25
Phase 31
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
11 of 13 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 83% of 18 pipeline programs.
Analysis
Trial Status
52
clinical trials
Completed16 · 31%
Recruiting13 · 25%
Active, not recruiting10 · 19%
Terminated5 · 10%
Not yet recruiting3 · 6%
Enrolling by invitation1 · 2%
Other4 · 8%
Clinical Trials
Trial Activity
52 trials
Expansion Study of ALT001 in Patients With Multiple System Atrophy
Recruiting·—·Phase 1·NCT07476352·60 enrolled
The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type
Recruiting·—·Phase 1·NCT07514923·20 enrolled
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
Recruiting·—·Phase 1·NCT06765733·20 enrolled
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
Recruiting·—·Phase 1/2·NCT06831500·36 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)